Dobermans of the Dow: 10 Stocks to Consider

2. Amgen Inc. (NASDAQ:AMGN)

Free Cash Flow Yield: 0.06

Number of Hedge Fund Holders: 72

Amgen Inc. (NASDAQ:AMGN) is a California-based multinational biopharmaceutical company. In the fourth quarter of 2024, the company reported revenue of $9.1 billion, which grew by 11% from the same period last year. The revenue also beat analysts’ estimates by $216.5 million. Product sales increased by 11%, largely due to a 14% rise in volume. When excluding revenue from the Horizon Therapeutics (Horizon) acquisition, sales saw a 10% uptick, with volume growth reaching 15%.

Amgen Inc. (NASDAQ:AMGN) is generating strong returns this year, surging by over 26% since the start of 2025. The market appears to overlook the company’s strong pipeline of innovations, particularly in oncology, which has been further strengthened by its acquisition of Horizon Therapeutics. This deal brings considerable growth potential, especially in the oncology segment. In addition, Amgen is actively engaged in developing promising obesity treatments, which could open the door to a multi-billion-dollar opportunity beginning in 2026.

Amgen Inc. (NASDAQ:AMGN)’s cash position also remained stable in the most recent quarter. The company’s free cash flow for the quarter came in at $4.4 billion, compared with $0.3 billion in the prior-year period. Its operating cash flow also jumped to $4.8 billion, from $0.5 billion in Q4 2023. During the quarter, it returned $1.2 billion to shareholders through dividends. Currently, it offers a quarterly dividend of $2.38 per share and has a dividend yield of 2.91%, as of March 10. The company’s dividend growth streak spans 13 years.